US equities
|
NVDA
$239.24
▲+0.14%
MU
$1,045.56
▼-1.73%
SPCX
$171.92
▲+0.49%
AMD
$649.42
▲+2.80%
MRVL
$287.01
▲+5.81%
AVGO
$375.81
▲+3.67%
INTC
$112.50
▼-3.18%
MSFT
$529.30
▲+0.78%
NVDA
$239.24
▲+0.14%
MU
$1,045.56
▼-1.73%
SPCX
$171.92
▲+0.49%
AMD
$649.42
▲+2.80%
MRVL
$287.01
▲+5.81%
AVGO
$375.81
▲+3.67%
INTC
$112.50
▼-3.18%
MSFT
$529.30
▲+0.78%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by CEVEC Pharmaceuticals GmbH
CEVEC's License Partner RZNOMICS Inc. Receives Approval to Initiate Clinical Development of CAP(R) Ad Technology-Produced Gene Therapy Vector in Liver Cancer Patients
July 13, 2022
From
CEVEC Pharmaceuticals GmbH
Via
AccessWire
CEVEC and UCB Sign Agreement for the use of CEVEC's ELEVECTA(R) AAV Manufacturing Technology in Gene Therapy
September 07, 2021
From
CEVEC Pharmaceuticals GmbH
Via
AccessWire
Topics
Intellectual Property
CEVEC Pharmaceuticals GmbH: CEVEC Closes Growth Financing Round to Serve Strong Demand in Viral Vector Technologies for Cell and Gene Therapies
July 27, 2021
From
CEVEC Pharmaceuticals GmbH
Via
AccessWire